BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M

BeOne Medicines Ltd.

Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.
BeOne retains share of royalty on annual ex-China net sales above $1.5B and all other Amgen collaboration rights.
IMDELLTRA is a DLL3-targeting bispecific T-cell engager approved in US for ES-SCLC after platinum chemo.
Transaction expected to close shortly; proceeds provide operational and strategic flexibility.

item 1.01item 2.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.